Drugs / E6 T Cell Receptor (TCR)
E6 T Cell Receptor (TCR)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03197025 | Jan 2018 → May 2019 | human papilloma virus infection, vulvar intraepithelial neoplasia | National Cancer Institute (NCI) | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | E6 T Cell Receptor (TCR) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03197025 ↗ |
| Known as | E6 TCR cells | “On day 0, the E6 TCR cells will be administered one time, intravenously over 20 to 30 minutes” NCT03197025 ↗ |
| Known as | E6 TCR T cells | “In this clinical trial the HPV-16 infection is targeted with a single infusion of autologous T cells that have been genetically engineered to express an HPV-16 E6-specific T...” NCT03197025 ↗ |
| Modality | Cell therapy | “The immune treatment in this study is called T cell therapy.” NCT03197025 ↗ |
| Route | Intravenous | “On day 0, the E6 TCR cells will be administered one time, intravenously over 20 to 30 minutes” NCT03197025 ↗ |